EP1572713A4 - Antisense modulation of acyl-coa synthetase 1 expression - Google Patents

Antisense modulation of acyl-coa synthetase 1 expression

Info

Publication number
EP1572713A4
EP1572713A4 EP03751855A EP03751855A EP1572713A4 EP 1572713 A4 EP1572713 A4 EP 1572713A4 EP 03751855 A EP03751855 A EP 03751855A EP 03751855 A EP03751855 A EP 03751855A EP 1572713 A4 EP1572713 A4 EP 1572713A4
Authority
EP
European Patent Office
Prior art keywords
expression
acyl
acs1
coa synthetase
antisense modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03751855A
Other languages
German (de)
French (fr)
Other versions
EP1572713A2 (en
Inventor
Stuart A Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of EP1572713A2 publication Critical patent/EP1572713A2/en
Publication of EP1572713A4 publication Critical patent/EP1572713A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Antisense compounds, compositions, and methods are provided for modulating the expression of acyl-Coa synthesis 1, heretofore referred to as ACS1. The compositions comprise antisense compounds, particulary antisense oligonucleotides, targeted to nucleic acids encoding ACS1. Methods of using these compounds for modulation of ACS1 expression and for treatment of diseases associated with expression of ACS1 are provided.
EP03751855A 2002-08-14 2003-08-14 Antisense modulation of acyl-coa synthetase 1 expression Withdrawn EP1572713A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40359102P 2002-08-14 2002-08-14
US403591P 2002-08-14
PCT/US2003/025389 WO2004016749A2 (en) 2002-08-14 2003-08-14 Antisense modulation of acyl-coa synthetase 1 expression

Publications (2)

Publication Number Publication Date
EP1572713A2 EP1572713A2 (en) 2005-09-14
EP1572713A4 true EP1572713A4 (en) 2006-05-24

Family

ID=31888248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03751855A Withdrawn EP1572713A4 (en) 2002-08-14 2003-08-14 Antisense modulation of acyl-coa synthetase 1 expression

Country Status (7)

Country Link
EP (1) EP1572713A4 (en)
JP (1) JP2006506976A (en)
AU (1) AU2003269962A1 (en)
BR (1) BR0313550A (en)
CA (1) CA2495037A1 (en)
MX (1) MXPA05001837A (en)
WO (1) WO2004016749A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888083B1 (en) * 2005-05-24 2011-12-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to lmw-ptpase
US20120035242A1 (en) * 2009-01-08 2012-02-09 Shionogi & Co., Ltd. Pharmaceutical composition for treating obesity or diabetes
JP2015082971A (en) * 2012-02-10 2015-04-30 国立大学法人大阪大学 Antisense oligonucleotide for acsl1
WO2015020194A1 (en) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Antisense oligonucleotide against acsl1
JP7190794B2 (en) 2017-03-29 2022-12-16 塩野義製薬株式会社 Complex of nucleic acid medicine and hyperbranched lipid
US20220267778A1 (en) 2019-07-30 2022-08-25 Shionogi & Co., Ltd. Nucleic acid drug targeting murf1
JPWO2021256297A1 (en) 2020-06-15 2021-12-23

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2003054159A2 (en) * 2001-12-19 2003-07-03 Exelixis, Inc. Modulating insulin receptor signaling through targeting facl

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
WO2003054159A2 (en) * 2001-12-19 2003-07-03 Exelixis, Inc. Modulating insulin receptor signaling through targeting facl

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 18 October 2002 (2002-10-18), "FACL1 related PCR primer SEQ ID No: 3", XP002373956, retrieved from EBI Database accession no. ADC51434 *
IKEMOTO S ET AL: "CHOLATE INHBITS HIGH-FAT DIET-INDUCED HYPERGLYCEMIA AND OBESITY WITH ACYL-COA SYNTHETASE MRNA DECREASE", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 273, no. 1, PART 1, July 1997 (1997-07-01), pages E37 - E45, XP009013253, ISSN: 0002-9513 *
LEWIN T M ET AL: "Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 27, 6 July 2001 (2001-07-06), pages 24674 - 24679, XP002269394, ISSN: 0021-9258 *
SMITH LISE ET AL: "Rational selection of antisense oligonucleotide sequences", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 11, no. 3, September 2000 (2000-09-01), pages 191 - 198, XP002372482, ISSN: 0928-0987 *
TAYLOR M F ET AL: "ANTISENSE OLIGONUCLEOTIDES: A SYSTEMATIC HIGH-THROUGHPUT APPROACH TO TARGET VALIDATION AND GENE FUNCTION DETERMINATION", DDT - DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, vol. 4, no. 12, December 1999 (1999-12-01), pages 562 - 567, XP002952061, ISSN: 1359-6446 *

Also Published As

Publication number Publication date
AU2003269962A8 (en) 2004-03-03
MXPA05001837A (en) 2005-04-19
BR0313550A (en) 2006-06-13
WO2004016749A3 (en) 2004-08-26
AU2003269962A1 (en) 2004-03-03
JP2006506976A (en) 2006-03-02
EP1572713A2 (en) 2005-09-14
WO2004016749A2 (en) 2004-02-26
CA2495037A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
WO2005049630A3 (en) Antisense modulation of kinesin-like 1 expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
WO2004071407A3 (en) Antisense modulation of ptp1b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2002010378A3 (en) Antisense modulation of ptp1b expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002095053A3 (en) Antisense modulation of src-c expression
EP1250347A4 (en) Antisense modulation of akt-3 expression
WO2003088921A3 (en) Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2004010956A3 (en) Antisense modulation of lar expression
WO2004016749A3 (en) Antisense modulation of acyl-coa synthetase 1 expression
WO2003099224A3 (en) Antisense moodulation of kinesin-like 1 expression
EP1235924A4 (en) Antisense modulation of rank expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
WO2004014299A3 (en) Antisense modulation of resistin expression
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression
WO2003099204A3 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
WO2004015126A3 (en) Antisense modulation of edg1 expression

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060406

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060609